市场见解

Why the Actinogen (ASX:ACW) share price is sinking 16% on Tuesday

A clinical trial update isn’t enough to draw investors in today.
The post Why the Actinogen (ASX:ACW) share price is sinking 16% on Tuesday appeared first on The Motley Fool Australia. –

Shares in Australian biotech Actinogen Medical Ltd (ASX: ACW) are crawling lower today, currently trading down 15.79% at 16 cents apiece.

Investors are selling Actinogen shares today despite the company receiving clearance from the US Food and Drug Administration (FDA) to commence a phase 2 trial on its Xanamem label.

Here are the details.

But first – what even is Actinogen Medical?

Actinogen is a biotechnology and research company. It is working on a medical breakthrough in neurological disorders that cause cognitive impairment.

Its lead drug candidate, Xanamem, is being investigated for potential breakthroughs in Alzheimer’s disease, Fragile X syndrome and other neurological diseases.

Many kinds of neurological conditions are either genetic, irreversible or have no known effective treatments – and unfortunately, no cure.

The compound works by modulating the ‘stress hormone’ cortisol, which has been shown to impair brain function and has been associated with several neurodegenerative conditions.

At the time of writing, Actinogen Medical has a market capitalisation of $317 million.

Why is the Actinogen share price sinking lower?

Actinogen advised it has received approval from the FDA to commence a Phase 2 trial on its Xanamem candidate, under an Investigational New Drug (IND) designation.

Being a Phase 2 trial, it is investigating the efficacy and safety of the Xanamem compound in treating male adolescents and young adults with Fragile X syndrome.

Fragile X syndrome is a hereditary disorder that causes mild to moderate intellectual disability, alongside behavioural and learning challenges.

It is thought to affect 1 in 4,000 males and 1 in 5,000–8,000 females worldwide. As observed, it primarily affects males, as it relates to genetics and the passing down of genes from parent to child.

Actinogen’s trial will enrol around 50 patients. The cohort will receive treatment over 12 weeks to observe the effects of Xanamem on Fragile X syndrome.

Investors can expect readouts from the study’s results sometime in 2023, per the announcement.

Aside from this, Actinogen also advised it had signed a letter of intent with Worldwide Clinical Trials Limited (WWC) to ‘operationalise’ the trial.

The move appears to be strategic from Actinogen, given that WWC is a research organisation that specialises in neurological, paediatric and rare diseases.

The letter of intent was signed for an amount of $944,724 and funds will be used “for start-up activities to enable prompt activation of [trial] sites”.

It has a duration of 60 days whilst a full contract is negotiated but can be cancelled with a full refund of any unused monies.

Actinogen Medical share price snapshot

It’s been a year of outsized returns for the Actinogen Medical share price, having posted a gain of 627% in the last 12 months after rallying 662% this year to date.

Each of these results has shot past the benchmark S&P/ASX 200 index (ASX: XJO)’s climb of around 20% in that time.

The post Why the Actinogen (ASX:ACW) share price is sinking 16% on Tuesday appeared first on The Motley Fool Australia.

Should you invest $1,000 in Actinogen Medical right now?

Before you consider Actinogen Medical, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Actinogen Medical wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

More reading

Pure Hydrogen (ASX:PH2) share price rockets 25% amid major plant production news

Here’s why the Betashares Crypto Innovators ETF (ASX:CRYP) share price is surging 7% today

Why Macquarie sees another 20% growth in the Megaport (ASX:MP1) share price

The NAB (ASX:NAB) dividend doubled in FY21: Here’s what you need to know

ANZ (ASX:ANZ) share price struggles despite CEO predicting economic boom

The author Zach Bristow has no positions in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

随时随地,交易世界!

移动APP平台,拥有 12 个市场的 50,000 多种全球上市证券(全球市值超过 70%),直接在您的 Android 或 iOS 设备上即可操作。

与独有的交易理念和投资分析工具相结合,帮助您在我们 12 个全球市场中的几乎所有金融工具上找到可操作的见解,从而帮助您优化交易策略。

推荐给您的朋友

向您的朋友推荐Monex并赠予他们免费使用我们交易工具的机会

我们尊重您的隐私,只会向您的朋友发送一封邮件 

与您的朋友分享

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!